BOSTON--(EON: Enhanced Online News)--MyndBlue (http://www.myndblue.io), an mHealth company which has developed a wearable-but-discreet medical device that is designed to detect a relapse of Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD) in advance of a crisis, announced today that it has won Second Prize in the “RESI (Redefining Early Stage Investments) San Francisco 2017” investment competition for early-stage life science companies.
“We are very excited that early-stage investors quickly comprehend the value proposition for MyndBlue, that our digital health solution alerts physicians with early-warning signs from their PTSD or MDD patients. MyndBlue thus represents a potentially transformational paradigm for treating mental health disorders”
MyndBlue allows doctors, for the first time, to use predictive markers to remotely detect evidence-based, early-warning signs in their patients of a likely relapse of Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) well before a crisis occurs. MDD and PTSD are treatable. Unfortunately, an overwhelming majority of these patients continue to suffer because they have no foreknowledge of a coming relapse of MDD and PTSD; they may have discontinued drug therapy or have ceased doctor visits. Now, via a discreetly wearable device, MyndBlue identifies specific predictive markers that detect instantly a patient’s disease-status changes and needs, signaling his/her doctor immediately for intervention, before a relapse of MDD and PTSD occurs.
“We are very excited that early-stage investors quickly comprehend the value proposition for MyndBlue, that our digital health solution alerts physicians with early-warning signs from their PTSD or MDD patients. MyndBlue thus represents a potentially transformational paradigm for treating mental health disorders,” said MyndBlue founder and CEO, Dr. Denis Fompeyrine.
NOW, A NEW PARADIGM FOR MENTAL-HEALTHCARE: PREDICTING RISK AHEAD OF TIME.
MDD and PTSD directly affect 24 million patients and their families. We know the toxicity of the diseases over the long term, and the irreversible sequelae they generate. The challenge is to free these millions of people from this disabling and dangerous mental suffering before they “cross over the line.” What is missing in the existing therapeutic arsenal to fight more effectively against these pathologies? Monitoring to detect the risks of MDD and PTSD crises ahead of time. For the first time, meaningful data can be measured in real time, very precisely, and on the basis of a clinical selection of biometric parameters directly associated with these pathologies of MDD and PTSD. A doctor is not permanently present with his patient; MDD and PTSD appear sneakily and trigger suddenly.
CAUTION: The MyndBlue technology is approved for investigational use only.